Linkage Biosciences is a molecular diagnostics company developing and marketing products that dramatically improve and expedite complex genetic testing. LinkSēq™ is the company’s Real-Time PCR genotyping product line. The company is headquartered in South San Francisco, California and has assembled an outstanding management team and scientific staff.
Zachary Antovich is the Founder of Linkage Biosciences and has served as President and CEO since the company started in March 2004.
Prior to this role, he was an executive with Applied Biosystems (acquired by Invitrogen) and has held various positions with both Bio-Rad Laboratories and Life Technologies Corp. (acquired by Invitrogen). Mr. Antovich also lived in Europe where he consulted with Genset SA. He began his career as a research scientist for Syntex Pharmaceuticals (acquired by Roche) where he developed early methods of RNA analysis from bone. Mr. Antovich graduated from the University of California, Irvine with a Bachelor of Science degree in Biological Sciences.
Board of Directors
Lewis J. Stuart
Lewis J. Stuart has more than 30 years of global healthcare commercial experience across multiple therapeutic categories including oncology, cardiovascular and infectious disease. Currently, Mr. Stuart is Vice-President of Sales and Marketing at Genomic Health, Inc., a global leader in molecular oncology and has responsibilities for the US breast and colon business. Prior to Genomic Health he served as President and General Manager for Phenogen Sciences, a new North American subsidiary of Melbourne, Australia-based, Genetic Technologies, Inc. Mr. Stuart spent over eight years in several commercial roles at CV Therapeutics, now a division of Gilead Sciences, Inc. and has held prior senior leadership roles at both Pfizer and Bristol Myers Squibb, most notably leading the launch of Viracept, a lifesaving treatment for HIV/AIDS. Mr. Stuart currently resides in the San Francisco Bay Area and received his BA in Marketing Communications at Virginia Tech and is pursuing an executive MBA at Northeastern University.
Peter D. Henig
Peter D. Henig is Managing Partner for Greenhouse Capital Partners. He is an active and experienced seed stage investor and a veteran business journalist whose work has appeared in the Red Herring, The Economist, Venture Capital Journal, and other noted publications. As a writer, editor and reporter, Mr. Henig specialized in covering public and private equity markets, technology startups, and emerging trends in business, finance and venture capital. He has effectively transferred that knowledge into a portfolio of successful private equity investments. Mr. Henig holds a Bachelor of Arts in Economics from Georgetown University and a Master of Arts in Economics and Public Policy from Stanford University.
Jeffrey Krauss is a Managing Member of PPC Enterprises LLC (“PPC”), a New York-based private equity firm. PPC is pursuing investment opportunities in small and middle market companies across several industries including healthcare. Mr. Krauss heads the healthcare team at PPC. Previously, Mr. Krauss was a Managing Member of Psilos Group Managers, LLC a private equity firm focused on investments in the healthcare services, healthcare information technology and medical technology segments of the healthcare industry. Mr. Krauss was previously a General Partner at Nazem & Company, a New York-based venture capital firm where he specialized in investments in the healthcare services and healthcare information technology segments. Prior to joining Nazem & Company, Mr. Krauss was an attorney with the law firm of Simpson, Thacher & Bartlett, where he specialized in private equity transactions and worked extensively on transactions originated by KKR. Mr. Krauss graduated magna cum laude with a Bachelor of Science degree in Accounting from the State University of New York at Albany and he graduated cum laude with a Juris Doctor degree from Harvard Law School.
Rebecca Bishop is a sales management executive at iRhythm Technologies, Inc., a company providing proprietary ambulatory cardiac monitoring devices and services. Previously, Ms. Bishop was a Clinical Market Development Director at Complete Genomics (Nasdaq: GNOM), a life sciences company commercializing a DNA sequencing services for whole genome sequencing and analysis. Ms. Bishop was also a management executive with Affymetrix, Inc. (Nasdaq: AFFX), the company that first introduced high density microarray technology to the life sciences marketplace. She also worked as the Microarray Marketing Director for MWG Scientific. Ms. Bishop began working in the life sciences space in 1993, holding executive positions with Curtin Matheson Scientific, Baxter, and Bio-Rad Laboratories.
Zachary Antovich is president and CEO of Linkage Biosciences, a company he founded in March 2004. Prior to this role, he was an executive with Applied Biosystems (acquired by Invitrogen) and has held various positions with both Bio-Rad Laboratories and Life Technologies Corp. (acquired by Invitrogen). Mr. Antovich also lived in Europe where he consulted with Genset SA. He began his career as a research scientist for Syntex Pharmaceuticals (acquired by Roche) where he developed early methods of RNA analysis from bone.
Scientific Advisory Board
Clifford Lowell, MD, PhD
Dr. Lowell is Professor and Chair Department of Laboratory Medicine, University of California, San Francisco. He received his M.D., Ph.D. degrees from Johns Hopkins School of Medicine in 1986. He completed his training in Internal Medicine at the Johns Hopkins Hospital (1989) and subspecialty training in Hematology/Oncology at UCSF (1993). His post-doctoral research fellowship training was done with Dr. Harold Varmus at UCSF (1989-1995), where Dr. Lowell developed his research interests in tyrosine kinase based signaling mechanisms. Dr. Lowell joined the faculty in the Dept. of Laboratory Medicine in 1995 and served as the Director of Clinical Immunology Laboratory through 2006. Dr. Lowell’s group continues to work on a variety of aspects of tyrosine kinases and intracellular signaling in innate immune cells. Dr. Lowell has authored over 150 peer-reviewed scientific manuscripts, received the prestigious Scholar Award from the Leukemia/Lymphoma Society, served as a member of the N.I.H. Innate Immunity Study Section, and completed one term as an editorial member of the Journal of Immunology. In 2006, Dr. Lowell was named Chairman of the Laboratory Medicine at UCSF with overall Departmental responsibility for Clinical Pathology, Transfusion Medicine and diagnostic testing at UCSF.
Radoje Drmanac, PhD
Dr. Drmanac is co-founder and Chief Science Officer of Complete Genomics, a high-performance DNA sequencing company founded in 2006 whose mission is to dramatically decrease the cost of DNA sequencing for research, drug development, and diagnostic applications. He is one of the leading research scientists and inventors in the field of genomics and massively parallel DNA sequencing (Science, 327, p78, 2010; Science, 336, p1110, 2012; Nature, 487, p190, 2012). In 1994 he co-founded Hyseq (later Nuvelo, now ARCA -NASDAQ symbol ABIO). As Chief Scientific Officer of Hyseq, he led the effort to discover and patent thousands of genes. Prior to Hyseq, he was a group leader at Argonne National Labs from 1991 to 1994 as part of the DOE Human Genome Project. He completed his postdoctoral studies in 1990 at ICRF in London. He received his Ph.D. in Molecular Biology in 1988 at Belgrade University for the conception and pioneering development of sequencing by hybridization, first massively parallel DNA sequencing technology. At the same university he received BS (1981) and MS (1985) degrees in Molecular Biology.
David Ginzinger, PhD
Dr. Ginzinger is an independent consultant for the life sciences industry. He is the former Vice President of Genomics Research and Applications at WaferGen Biosystems, a company developing next generation real time PCR technology. Dr. Ginzinger moved to WaferGen from University of California, San Francisco where he was Director of Operations at the Center for Molecular Oncology, Comprehensive Cancer Center. Prior to this role, he was Director of Scientific Operations and Leader of Advanced Scientific Applications at Applied Biosystems (Life Technologies Corp). Dr. Ginzinger has considerable expertise in the areas of gene expression analysis, polymorphism (SNP) detection, and DNA sequencing, most notably in the area of cancer research. He has developed over 1000 assays for clinical and basic research applications.